Hybrid heart valves

Information

  • Patent Grant
  • 11654020
  • Patent Number
    11,654,020
  • Date Filed
    Monday, October 28, 2019
    5 years ago
  • Date Issued
    Tuesday, May 23, 2023
    a year ago
Abstract
A prosthetic heart valve configured to replace a native heart valve and having a support frame configured to be reshaped into an expanded form in order to receive and/or support an expandable prosthetic heart valve therein is disclosed, together with methods of using same. The prosthetic heart valve may be configured to have a generally rigid and/or expansion-resistant configuration when initially implanted to replace a native valve (or other prosthetic heart valve), but to assume a generally expanded form when subjected to an outward force such as that provided by a dilation balloon or other mechanical expander. An inflow stent frame is expandable for anchoring the valve in place, and may have an outflow end that is collapsible to a limited degree for delivery and expandable post-implant to facilitate valve-in-valve (ViV) procedures. The hybrid heart valves eliminate earlier structural bands, which both reduces manufacturing time and facilitates ViV procedures.
Description
TECHNICAL FIELD

The present disclosure relates to a hybrid heart valve for heart valve replacement, and more particularly to modifications to simplify the construction of hybrid heart valves.


BACKGROUND

The heart is a hollow muscular organ having four pumping chambers separated by four heart valves: aortic, mitral (or bicuspid), tricuspid, and pulmonary. Heart valves are comprised of a dense fibrous ring known as the annulus, and leaflets or cusps attached to the annulus.


Heart valve disease is a widespread condition in which one or more of the valves of the heart fails to function properly. In a traditional valve replacement operation, the damaged leaflets are typically excised and the annulus sculpted to receive a replacement prosthetic valve.


In tissue-type valves, a whole xenograft valve (e.g., porcine) or a plurality of xenograft leaflets (e.g., bovine pericardium) can provide fluid occluding surfaces. Synthetic leaflets have been proposed, and thus the term “flexible leaflet valve” refers to both natural and artificial “tissue-type” valves. In a typical tissue-type valve, two or more flexible leaflets are mounted within a peripheral support structure that usually includes posts or commissures extending in the outflow direction to mimic natural fibrous commissures in the native annulus. The metallic or polymeric “support frame,” sometimes called a “wireform” or “stent,” has a plurality (typically three) of large radius cusps supporting the cusp region of the flexible leaflets (e.g., either a whole xenograft valve or three separate leaflets). The ends of each pair of adjacent cusps converge somewhat asymptotically to form upstanding commissures that terminate in tips, each extending in the opposite direction as the arcuate cusps and having a relatively smaller radius. Components of the valve are usually assembled with one or more biocompatible fabrics (e.g., polyester, for example, Dacron® polyethylene terephthalate (PET)) coverings, and a fabric-covered sewing ring is provided on the inflow end of the peripheral support structure.


There is a need for a prosthetic valve that can be surgically implanted in a body channel in a more efficient procedure so as to reduce the time required on extracorporeal circulation. One solution especially for aortic valve replacement is provided by the Edwards Intuity® valve system available from Edwards Lifesciences of Irvine, Calif. Aspects of the Edwards Intuity® valve system are disclosed in U.S. Pat. No. 8,641,757 to Pintor, et al. The Edwards Intuity® valve is a hybrid of a surgical valve and a plastically-expandable stent that helps secure the valve in place in a shorter amount of time.


Despite certain advances in this area, there remains a need for a simplified prosthetic heart valve that facilitates implant and simplifies manufacturing techniques.


SUMMARY

The application discloses a hybrid prosthetic heart valve (and methods for making the same) having a stent frame positioned at the inflow end of the prosthetic heart valve configured to plastically expand into a substantially flared shape when subjected to a dilation force that is by itself insufficient to cause expansion of the main support structure. The stent frame is positioned upstream or on the inflow end of the entire valve portion. The application also discloses a hybrid prosthetic heart valve configured to receive a prosthetic heart valve, such as a catheter-deployed (transcatheter) prosthetic heart valve, therein—e.g., it is adapted for valve-in-valve (ViV) procedures.


An exemplary hybrid prosthetic heart valve having an inflow end and an outflow end, and comprises a valve member including a plurality of flexible leaflets configured to ensure one-way blood flow therethrough. A generally tubular expandable inflow stent frame having a radially-expandable inflow end and an outflow end is secured to and projects from an inflow end of the valve member. The outflow end of the stent frame undulates with peaks and valleys, and the outflow end includes integrated commissure posts to which the leaflets attach. The outflow end of the stent frame has a circumferential structure defining a nominal diameter that enables physiological functioning of the valve member when implanted. The circumferential structure is radially expandable from the nominal diameter to a larger expanded diameter upon application of an outward dilatory force from within the stent frame substantially larger than forces associated with normal physiological use. And the circumferential structure has limited radially compressibility of between about 7-20% of the nominal diameter to reduce the size of the outflow end during delivery of the heart valve.


A further hybrid prosthetic heart valve disclosed herein and adapted for post-implant expansion has an inflow end and an outflow end with a valve member and an inflow stent frame. The valve member includes an undulating wireform supporting a plurality of flexible leaflets configured to ensure one-way blood flow therethrough. The stent frame is plastically-expandable with a radially-expandable inflow end and an outflow end secured to an inflow end of the wireform. The stent frame projects from the inflow end of the wireform and the outflow end undulates with peaks and valleys corresponding to the wireform. The outflow end further includes integrated commissure posts to which the leaflets attach, and defines an implant circumference that is non-compressible in normal physiological use and has a nominal diameter. The stent frame outflow end permits expansion from the nominal diameter to a second diameter larger than the nominal diameter upon application of an outward dilatory force from within the outflow end substantially larger than forces associated with normal physiological use.


Another hybrid prosthetic heart valve disclosed herein comprises a valve member including an undulating wireform supporting a plurality of flexible leaflets configured to ensure one-way blood flow therethrough. A plastically-expandable inflow stent frame having a radially-expandable inflow end and an outflow end is secured to an inflow end of the wireform. The stent frame projects from the inflow end of the wireform and the outflow end undulates with peaks and valleys corresponding to the wireform. The outflow end includes integrated commissure posts to which the leaflets attach outside of the wireform, and the outflow end comprises a circumferential structure defining a nominal diameter that enables functioning of the valve member. The circumferential structure is radially compressible to a smaller contracted diameter to enable compression of the outflow end during delivery of the heart valve, and radially expandable from the nominal diameter to a larger expanded diameter upon application of an outward dilatory force from within the stent frame substantially larger than forces associated with normal physiological use.


Other features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings that illustrate, by way of example, the principles of the invention.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is an exploded view of an inner structural band subassembly of a prior art prosthetic heart valve, and FIG. 1B shows the band subassembly having been covered with cloth and exploded over a peripheral sealing ring;



FIG. 1C shows the cloth-covered band subassembly joined with the peripheral sealing ring also covered in cloth, while FIG. 1D is a vertical sectional view through a cusp region thereof;



FIG. 2A is a perspective view of a flexible leaflet subassembly for use in the prior art prosthetic heart valve, and FIG. 2B shows an undulating wireform used for support thereof;



FIG. 2C is a perspective view of a subassembly of the undulating wireform covered in fabric, and FIG. 2D is a detailed sectional view of a cusp portion thereof;



FIG. 2E shows a leaflet and wireform subassembly for prior art prosthetic heart valves;



FIG. 3 is a perspective view of a finished prior art prosthetic heart valve including the combination of the subassemblies shown in FIGS. 1C and 2E;



FIGS. 4A and 4B are inflow and outflow perspective views, respectively, of a prosthetic heart valve as in FIG. 3 before coupling with an inflow anchoring skirt to form a hybrid prosthetic heart valve;



FIG. 5 is an exploded assembly view of a portion of a cloth-covered anchoring skirt for coupling to the heart valve;



FIG. 6 is an exploded assembly view of the portion of the cloth-covered anchoring skirt shown in FIG. 5 and a lower sealing flange secured thereto to form the inflow anchoring skirt;



FIG. 7A shows the valve member above the cloth-covered anchoring skirt and schematically shows one method of coupling the two elements, while FIG. 7B illustrates an inner plastically-expandable stent frame of the anchoring skirt and the pattern of coupling sutures passed therethrough;



FIG. 8A is a side view of a hybrid prosthetic heart valve of the present application, while FIG. 8B shows an anchoring skirt therefor with a valve member in phantom, and FIG. 8C is a perspective view of the prosthetic heart valve with portions cutaway to reveal internal structural leaflet supports;



FIGS. 9A-9C are perspective views of an exemplary anchoring skirt for use in the hybrid prosthetic heart valve of FIGS. 8A-8C;



FIG. 10A is an exploded perspective view of components of an alternative hybrid prosthetic heart valve, while FIG. 10B shows an exemplary leaflet and wireform subassembly and an anchoring skirt and commissure post subassembly for the hybrid prosthetic heart valve;



FIGS. 10C and 10D show details of separate commissure posts;



FIG. 11 is another exploded perspective view of subassemblies of the alternative hybrid prosthetic heart valve;



FIG. 12 shows the relative positions of the anchoring skirt and commissure post subassembly and wireform for the alternative hybrid prosthetic heart valve, and FIGS. 12A-12D are further detailed views thereof;



FIG. 13 is a perspective view of the finished hybrid prosthetic heart valve;



FIGS. 14A and 14B are perspective views of a hybrid prosthetic heart valve built using the methods of FIGS. 15-16;



FIGS. 15A and 15B show steps for covering an anchoring frame member with cloth in the disclosed method of hybrid valve construction;



FIGS. 16A and 16B show methods of attachment of a suture permeable sealing ring to the anchoring frame member;



FIG. 17 is a perspective view of a separate commissure post, and FIG. 18 is the commissure post covered with cloth;



FIGS. 19A and 19B are elevational views of an exemplary integrated frame member of the present application;



FIG. 20 is an alternative commissure post;



FIG. 21 is a tubular legs of fabric used to cover the separate commissure posts;



FIGS. 22A and 22B are perspective views of a cloth-covered commissure post secured to an outflow edge of a cloth-covered anchoring frame member;



FIG. 23 illustrates alternative commissure posts, and FIG. 24 shows one alternative commissure post secured to an outflow edge of a cloth-covered anchoring frame member;



FIGS. 25A-25D are perspective, elevational, and flat plan views of an exemplary integrated frame member for use in the hybrid prosthetic heart valves disclosed herein;



FIGS. 26A-26D are several views of an alternative integrated frame member much like that shown in FIGS. 25A-25D but with commissure posts that are separated from a lower expandable frame;



FIGS. 27A and 27B are perspective and elevational views of a still further integrated frame member of the present application that is non-collapsible and non-expandable;



FIGS. 28A and 28B are perspective and elevational views of another integrated frame member with separate commissure posts;



FIG. 29 is a perspective view of an alternative integrated frame member having an expandable frame connected to a polymer band that forms commissure posts;



FIGS. 30A and 30B are elevational and perspective views of an exemplary expandable frame for use in the frame member of FIG. 29; and



FIG. 31 is an elevational view of an integrated frame member similar to that shown in FIG. 29 with the polymer band overlapping an upper edge of the expandable frame.





DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

The prosthetic heart valves disclosed herein are “hybrid” in that they include a prosthetic valve member with a relatively stable diameter, and a lower expandable frame structure to help in anchoring the valve in place. Most prior valves have either a wholly non-compressible/non-expandable valve member or a wholly expandable frame structure that incorporates a valve therein. One specific commercial prosthetic heart valve that is constructed in a hybrid manner is the Edwards Intuity® valve system from Edwards Lifesciences of Irvine, Calif. The hybrid Edwards Intuity® valve system comprises a surgical non-compressible/non-expandable valve member (e.g., Edwards Magna Ease® valve) having bioprosthetic (e.g., bovine pericardial) leaflets coupled to a stainless steel expandable frame structure on its inflow end.



FIGS. 1-7 illustrate a number of steps in the construction of an exemplary hybrid prosthetic heart valve 20.



FIG. 1A is an exploded view of an inner structural band subassembly 40, and FIG. 1B shows the band subassembly having been covered with cloth and exploded over a peripheral sealing ring. The inner structural band subassembly 40 includes an inner polymer band 42 having three upstanding posts 44 and a scalloped lower ring 46, and an outer more rigid band 48 having a scalloped shape to conform to the lower ring 46. The band subassembly 40 is formed by positioning the polymer band 42 within the rigid band 48 and securing them together with sutures through aligned holes, for example.



FIG. 1B is a perspective view of the assembled band subassembly 40 covered in cloth exploded from a sewing ring 68. The two structural bands 42, 48 are the same heights in the cusp region and encompassed by a fabric cover 64 that is rolled into a peripheral tab 66. As seen in FIG. 1D, the sewing ring 62 comprises an inner suture permeable member 68 having a frustoconical form and encompassed by a second fabric cover 70. Two fabric covers 64, 70 are sewn together at a lower junction point 72 to form the cloth-covered assembly of FIG. 1C, while FIG. 1D shows details through a cusp portion thereof.



FIG. 2A is a perspective view of a flexible leaflet subassembly and FIG. 2B shows an undulating wireform used for support thereof. FIG. 2C is a perspective view of a cloth-covered wireform subassembly 50, and FIG. 2D is a detailed sectional view of a cusp portion of the wireform 50 showing an inner wire member 52 covered with fabric that defines a tubular portion 54 and an outwardly projecting flap 56. The wireform 50 defines three upstanding commissure posts 58 and three downwardly convex cusps 60. This is a standard shape for tri-leaflet heart valves and mimics the peripheral edges of the three native aortic leaflets. The shape of the wireform 50 coincides with the upper edge of the band subassembly 40, and defines the outflow edge of the prosthetic valve 20. The wireform subassembly 50 is then joined together with the flexible leaflet subassembly, as seen in FIG. 2E.



FIG. 3 is a perspective view of a finished valve member including the combination of the subassemblies shown in FIGS. 1C and 2E.



FIGS. 4A and 4B are inflow and outflow perspective views, respectively, of the surgical heart valve member 24 before coupling with an inflow anchoring skirt to form the hybrid heart valve 20. Although construction details are not shown, three flexible leaflets 74 are secured along the undulating wireform 50 and then to the combination of the band subassembly 40 and sewing ring 62 shown in FIG. 1C. In a preferred embodiment, each of the three leaflets includes outwardly projecting tabs that pass through the inverted U-shaped commissure posts 58 and wrap around the cloth-covered commissure posts 75 (see FIG. 1C) of the band subassembly 40. The entire structure at the commissures is covered with a secondary fabric to form the valve commissures 35 as seen in FIG. 7A.


One feature of the valve member 24 that is considered particularly important is the sewing ring 62 that surrounds the inflow end thereof. As will be seen, the sewing ring 62 is used to attach the anchoring skirt 26 to the valve member 24. Moreover, the sewing ring 62 presents an outward flange that contacts an atrial side of the annulus, while the anchoring skirt 26 expands and contracts the opposite, ventricular side of the annulus, therefore securing the heart valve 20 to the annulus from both sides. Furthermore, the presence of the sewing ring 62 provides an opportunity for the surgeon to use conventional sutures to secure the heart valve 20 to the annulus as a contingency.


The preferred sewing ring 62 defines a relatively planar upper or outflow face and an undulating lower face. Cusps of the valve structure abut the sewing ring upper face opposite locations where the lower face defines peaks. Conversely, the valve commissure posts align with locations where the sewing ring lower face defines troughs. The undulating shape of the lower face advantageously matches the anatomical contours of the aortic side of the annulus AA, that is, the supra-annular shelf. The ring 62 preferably comprises a suture-permeable material such as rolled synthetic fabric or a silicone inner core covered by a synthetic fabric. In the latter case, the silicone may be molded to define the contour of the lower face and the fabric cover conforms thereover.


Now with reference to FIGS. 5 and 6, assembly of the cloth-covered anchoring skirt 26 will be described. FIG. 5 is an exploded assembly view of a portion of a cloth-covered anchoring skirt for coupling to the valve member, and FIG. 6 is an exploded assembly view of the portion of the cloth-covered anchoring skirt shown in FIG. 5 and a lower sealing flange secured thereto to form the inflow anchoring skirt. It should first be noted that the size of the anchoring skirt 26 will vary depending on the overall size of the heart valve 20. Therefore the following discussion applies to all sizes of valve components, with the dimensions scaled accordingly.


The general function of the anchoring skirt 26 is to provide the means to attach the prosthetic valve member 24 to the native aortic root. The anchoring skirt 26 may be a pre-crimped, tapered, 316L stainless steel balloon-expandable stent, desirably covered by a polyester fabric to help seal against paravalvular leakage and to promote tissue ingrowth once implanted within the annulus. The anchoring skirt 26 transitions between the tapered, constricted shape of FIG. 5B to a flared, expanded shape. The anchoring skirt 26 comprises an inner stent frame 80, a fabric covering 82, and a band-like lower sealing flange 84. The stent frame 80 assembles within a tubular section of fabric 82, which is then drawn taut around the stent frame, inside and out, and sewn thereto to form the intermediate cloth-covered frame 88 in FIG. 5. During this assembly process, the stent frame 80 is desirably tubular, though later the frame will be crimped to a conical shape as see in FIG. 7B for example. A particular sequence for attaching the tubular section of fabric 82 around the stent frame 80 includes providing longitudinal suture markers (not shown) at 120° locations around the fabric to enable registration with similarly circumferentially-spaced, commissure features on the stent frame. After surrounding the stent frame 80 with the fabric 82, a series of longitudinal sutures at each of the three 120° locations secure the two components together. Furthermore, a series of stitches are provided along the undulating upper end 86 of the stent frame 80 to complete the fabric enclosure. In one embodiment, the tubular section of fabric 82 comprises polytetrafluoroethylene (PTFE) cloth, although other biocompatible fabrics may be used. Subsequently, the lower sealing flange 84 shown in FIG. 6 is attached circumferentially around a lower edge of the intermediate cloth-covered frame 88.



FIG. 7A shows the valve member above the cloth-covered anchoring skirt and schematically shows one method of couple the two elements using sutures. FIG. 7B illustrates the inner plastically-expandable stent frame 80 with cloth covering removed to indicate a preferred pattern of coupling sutures passed therethrough. The anchoring skirt 26 preferably attaches to the sewing ring 62 during the manufacturing process in a way that preserves the integrity of the ring and prevents reduction of the valve's effective orifice area (EOA). Desirably, the anchoring skirt 26 will be continuously sutured to the ring 62 in a manner that maintains the contours of the ring. In this regard, sutures may be passed through apertures or eyelets 92 arrayed along the upper or first end 86 of the inner stent frame 80. Other connection solutions include prongs or hooks extending inward from the stent, ties, hook-and-loop fasteners (e.g., Velcro® fasteners), snaps, adhesives, etc. Alternatively, the anchoring skirt 26 may be more rigidly connected to rigid components within the prosthetic valve member 24.


The construction steps described above in FIGS. 1-7 are relatively detailed and time-consuming. Current hybrid valves such as described above take 11-12 hours total to build. This includes building a valve member, as in FIGS. 1-3, which takes approximately 7.5 hours, and then covering the stent frame 80 with cloth and attaching it to the valve member, which combined take another 3-4 hours of time. It would therefore be desirable to reduce the labor hours to build such a valve.


Moreover, the aforementioned hybrid valve system does not have expandability during a valve-in-valve (ViV) procedure due to both the relatively rigid band subassembly 40 as well as the anchoring stent frame 80. Some attempts at making prosthetic valves expandable for ViV are known, but the resulting valve is expensive and difficult to build. Consequently, the present application discloses a number of configurations of hybrid valves and methods of making that simplify the assembly and result in a ViV-adapted hybrid valve.



FIGS. 8A-8C illustrate a hybrid prosthetic heart valve 170 of the present application, which includes an upper valve member 172 coupled to a cloth-covered anchoring skirt 174. FIG. 8B shows the valve member 172 in phantom to illustrate the contours of an expandable frame 176 of the anchoring skirt 174, and FIG. 8C is a perspective view of the entire heart valve 170 with portions at one commissure post 178 cutaway to reveal internal structural leaflet supports.


The valve member 172 of the hybrid prosthetic heart valve 170 shares some structural aspects with the prior art valve member illustrated in FIG. 3. In particular, there are three upstanding commissure posts 178 alternating with three arcuate cusps 180 curving in an inflow direction. Three flexible leaflets 182 are supported by the commissure posts 178 and cusps 180 and extend across a generally cylindrical flow orifice defined therewithin. The leaflets 182 are attached to an up and down undulating typically metallic wireform 184 via a cloth covering. As with earlier valve constructions, the upstanding posts 186 rise up adjacent to and just outside of the commissures of the wireform 184, and outer tabs 188 of the leaflets 182 extend underneath the wireform, wrap around the posts, and are secured thereto with sutures.


In the illustrated embodiment, the heart valve 170 also includes a highly compliant sealing ring 190 extending outward therefrom at approximately the interface between the valve member 172 and the anchoring skirt 174. The sealing ring 190 as well as the expandable frame 176 are covered with a fabric 192 that helps prevent leakage around the outside of the valve once implanted. Furthermore, the sealing ring 190 is also suture-permeable and may be used to secure the valve in place in the native annulus.



FIGS. 9A-9C illustrate details of the exemplary expandable frame 176 for use in the hybrid prosthetic heart valve 170 of FIGS. 8A-8C.


With specific reference to FIG. 9A, the lower frame 176 is shown in perspective and includes a plurality of circumferential row struts connected by a series of spaced axial column struts. Specifically, an upper or outflow row strut 200 extends continuously around a periphery of the frame 176, and preferably follows a gently undulating path so as to match a similar shape of the underside of the upper valve member 172 (FIG. 8B). As seen in FIG. 9A, three peaks 204 along the upper row strut 200 correspond to the locations of the commissures 178 of the valve 170. In general, the lower frame 176 attaches to an inflow end of the upper valve member 172, and preferably directly to or to fabric covering the internal support frame. The lower frame 176 is initially generally tubular and expands to be somewhat conical with the free end farthest from the upper valve member 172 expanding outward but the end closest remaining the same diameter.


The upper row strut 200 includes a plurality of eyeholes 202 evenly spaced apart and located just below the top edge thereof that are useful for securing the frame 176 to the fabric of the underside of the valve member 172. A series of axial column struts 206 depend downward from the upper row strut 200, and specifically from each of the eyeholes 202, and connect the upper row strut to two lower row struts 208. The lower row struts 208 circumscribe the frame 176 in zig-zag patterns, with an inverted “V” shape between each two adjacent column struts 206. The lower row struts 208 preferably traverse horizontally around the frame, and the length of the column struts 206 thus varies with the undulating upper row strut 200.


As mentioned above, the lower frame 176, in particular the inflow end thereof, may be plastically expanded, such as by balloon expansion, and may be formed of a plastically expandable material, for example, stainless steel or cobalt-chromium (e.g., Elgiloy® alloy). Alternatively, the lower frame 176 may be self-expanding, such as being formed from nitinol. In a conventional Edwards Intuity® valve, the upper row strut 200 is generally ring-like without capacity for compression or expansion. In the illustrated frame 176, on the other hand, a series of spaced notches 210 are provided that permit expansion and contraction. That is, circumferential segments of the strut 250 are interrupted by the V-shaped notches 210 that permits a limited amount of expansion, perhaps 3 mm in diameter, to accommodate a supplemental expandable valve to be inserted and expanded therein. More particularly, the upper row strut 200 (outflow end) of the frame 176 defines a nominal diameter seen in FIG. 9A that enables functioning of the valve member 172. The upper row strut 200 is radially compressible from the nominal diameter to a smaller contracted diameter to enable compression of the outflow end of the frame 176 during delivery of the heart valve. The upper row strut 200 is also radially expandable from the nominal diameter to a larger expanded diameter upon application of an outward dilatory force from within the stent frame such as in a valve-in-valve procedure.


It should be understood that the preferred embodiment of the hybrid prosthetic heart valve 170 is configured for surgical delivery, which differs from transcatheter or transapical delivery. In the latter cases, prosthetic heart valves are formed of structures and materials that enable substantial compression of the valve into a relatively small diameter profile, to enable delivery through the vasculature (e.g., transcatheter) or directly into the heart through an introducer (e.g., transapical). The hybrid prosthetic heart valve 170, on the other hand, is typically delivered via open heart surgery or a less invasive version thereof, such as through a mid-thoracotomy. “Surgical” delivery of heart valves requires that the heart be stopped and the patient be placed on cardiopulmonary bypass, while transcatheter and transapical procedures may be done on a beating heart. Therefore, the hybrid prosthetic heart valves 170 disclosed herein are only compressible to a limited degree, to enable a smaller delivery profile, but not totally compressible.


As shown in FIG. 9B, the modified frame 176 can be collapsed to a pre-determined minimum diameter for delivery and expanded to a pre-determined maximum diameter during a valve-in-valve procedure. More specifically, the upper row strut 200 of the illustrated frame 176 may be collapsed by 2 mm relative to the nominal diameter for ease of delivery by compressing the V-shaped notches 210 as indicated. Because the notches 210 can only be compressed until the two corners meet, the frame 176 can only be collapsed by a predetermined amount. The exemplary frame 176 is specifically designed to be collapsible to ease insertion through small incisions when the valve is implanted and for ease of seating in the annulus. The amount of collapse could be as large as about 40-50% by diameter, but would more preferably be about 2-3 mm, or between about 7-20% for heart valves having nominal operating diameters between about 19-29 mm. A compression of 2 mm in diameter, for example, corresponds to a change in circumference of about 6.28 mm. The stent frame is divided into 18 segments around its circumference by the axial column struts 206. Therefore, by placing an initial gap of 0.35 mm (6.28 mm/18) in each segment, the frame can collapse by 2 mm in diameter before adjacent segments make contact and hence prevent further compression.



FIG. 9C discloses that the upper row strut 200 of the illustrated frame 176 may be subsequently expanded by up to 3 mm relative to a nominal diameter during a valve-in-valve procedure. Because of the configuration of the upper row of struts, the outflow portion of the frame cannot be expanded more than 3 mm. That is, the V-shaped notches 210 eventually straighten out, which prevents further expansion. Desirably, the frame is designed to expand 3 mm in diameter beyond its nominal diameter. The nominal diameter is defined when the notches 210 are V-shaped, prior to either contraction or expansion. Similar to the gaps for limiting compression, the 3 mm in expansion corresponds to an about 9.42 mm (3 mm×n) change in circumference. Therefore, each of the 18 segments limits expansion to 9.42 mm/18=about 0.52 mm. In this example, the length of the “V” shaped struts connecting each segment are thus 0.52 mm+0.35 mm (from the compression gaps)=0.87 mm During a valve-in-valve expansion, the expansion of the stent frame would be limited by the expansion-limiting struts at the point where they became straight across the gap between adjacent frame segments.


If it is not desired to have the frame collapsible but expansion is still desired, the gaps could be reduced to the practical limit of laser cutting, for example, about 25 μm. With 18 gaps of 25 μm, the total amount of compression would be (18×25 μm/n)=0.143 mm (about 0.006″).


In contrast, some earlier designs simply removed the upper row of struts that defines the outflow diameter of the frame. Such a frame configuration had no built-in way to limit the maximum expansion of the valve during a valve-in-valve procedure. Additionally, there could be an advantage to having hybrid valves that are collapsed by a limited amount, for example, about 2-3 mm, for easier insertion. While a frame without an upper row of struts could be collapsed, there is no built-in limit the amount of compression. It might be desirable to have the maximum compression amount limited as disclosed herein for consistency and for preventing physicians from trying to collapse the valve more than it can safely be collapsed.


In addition, a number of valve-type indicators 212 are integrated into the frame 176 at locations around its circumference, such as three valve size indicators. In the illustrated embodiment, the valve size indicators 212 comprise small plate-like tags inscribed with the numerical valve size in mm, for example 21 mm in the illustrated embodiment. The use of any alphanumeric characters and/or symbols that signify size or other feature of the valve are contemplated. The frame 176 may be laser cut from a tubular blank, with the plate-like size indicators 212 left connected to one more of the struts. As shown, the size indicators 212 are located just below the peaks 204 of the undulating upper row strut 200, connected between the corresponding eyehole 252 and the descending column strut 206. There are thus three size indicators 212 spaced about 120° apart around the frame 176. This location provides additional space between the upper row strut 200 and the adjacent lower row strut 208. The inscribed or cutout valve size numerals are sufficiently large to be visualized with X-ray, Transesophageal Echocardiogram (TEE), or other imaging modality. In one embodiment, the valve size numerals are from about 1.5 mm to about 2 mm in height, for example, about 1.75 mm in height.



FIG. 10A is an exploded perspective view of components of an alternative hybrid prosthetic heart valve 300. The alternative heart valve 300 does away with an internal stent or support frame previously shown as the composite bands 42, 48 in FIG. 1A, for example. The composite band structure was the primary source of circumferential rigidity to the heart valves in which they were employed, and thus an expansion structure enabled valve-in-valve procedures. The alternative hybrid heart valve 300 includes a lower compressible/expandable frame 302, as before, separate commissure posts 304 that are secured to the frame, and an undulating wireform 306 supporting flexible leaflets 308, also as before.



FIG. 10B shows a subassembly 310 including the wireform 306 juxtaposed with the three leaflets 308, and an “integrated” subassembly 312 of the expandable frame 302 with the commissure posts 304 attached thereto. Each of the flexible leaflets 308 has two tabs 309, and pairs of tabs on adjacent leaflets are shown projecting through (under) the inverted V-shaped commissures of the wireform 306. These pairs of tabs 309 then wrap around one of the upstanding commissure posts 304 of the subassembly 312, which are located adjacent to and radially outward from the wireform commissures. The subassemblies 310, 312 are eventually covered with biocompatible fabric such as polyester, and the pairs of tabs 309 and commissure posts 304 are secured to each other with a cloth covering (see FIG. 13).


Due to the attachment of the commissure posts 304 to the frame 302 the subassembly 312 integrates the frame and commissure posts, while as described below, an “integrated” frame may mean that the commissure posts are integrally formed of the same homogeneous material as the rest of the stent frame. Integrated in this sense meaning the two components are securely attached together prior to assembly with the wireform/leaflet subassembly 310, either by securing the two parts or forming them at the same time from the same material. Furthermore, a hybrid heart valve with an “integrated” frame means that the frame provides both the expandable skirt frame as well as commissure posts to which the leaflets attach, without any additional structural bands, such as the metal band 48 seen in FIG. 1A. With this configuration, the number of parts in the valve is reduced, which reduces assembly time and expense.



FIGS. 10C and 10D illustrate a commissure post 304 from an outer and an inner perspective, respectively. A lower end of each of the commissure posts 304 includes a concave ledge 314 that matches the contour of one of the peaks 316 in the undulating upper row of struts 318 of the expandable frame. As seen in FIG. 10B, an outer plate 320 below each of the concave ledges 314 of the commissure posts 304 extends downward on the outside of the expandable frame 302. Sutures 322 secure the commissure posts 304 to the frame 302 via suture holes 324 that align with eyeholes 326 at the peaks 316 of the undulating upper row strut 318. This shape matching followed by covering with fabric provides a relatively stable arrangement of the commissure posts 304 in the integrated frame subassembly 312.



FIG. 11 is another exploded perspective view of subassemblies of the alternative hybrid prosthetic heart valve 300. In this view, the wireform in the subassembly 310 of the wireform and leaflets has been covered with fabric, and features an outwardly projecting flap 330. The fabric flap 330 is used to secure the wireform/leaflet subassembly 310 to the subassembly 312 of the expandable frame 302 and commissure posts 304. Furthermore, a suture-permeable sealing ring 332 may be attached such as by sewing at the juxtaposition between the two subassemblies 310, 312.


The relative positions of the wireform 306 and the frame/commissure post subassembly 312 is seen in FIG. 12, and also in further detail in FIGS. 12A-12D, with the commissure posts 304 immediately outside of the commissures of the wireform 306. Finally, FIG. 13 is a perspective view of the finished hybrid prosthetic heart valve 300 entirely covered with fabric.


The removal of the aforementioned stent bands and attachment (integration) of the commissure posts 304 directly to the frame 302 greatly simplifies construction, reduces labor hours, lowers the radial profile of the valve by ˜1.6 mm, and allows for expansion during a valve-in-valve procedure. A preferred construction sequence involves attaching the sealing ring 332 to the expandable frame 302, along with three cloth-covered commissure posts 304, then attaching this assembly to the wireform/leaflet subassembly 310 during final assembly.


The commissure posts 304 disclosed have specific features that interface with the frame 304 to add stability to the posts in all directions. That is, the specific surfaces 314, 320 that mate with the corresponding peaks 316 on the frame 302 as well as the holes 324 that allow the posts to attach with sutures 322 to the frame provide excellent stability in all directions for subsequent covering with fabric. The commissure posts 304 could be molded from polyester or some other biocompatible material into the shape shown here, or even produced using 3D printing.


A hybrid valve 340 built using the disclosed methods is shown in FIGS. 14A and 14B with all but flexible leaflets 342 covered with cloth. The improved valve construction disclosed herein eliminates a separate stent subassembly by combining the functions of that assembly (supporting the leaflets from underneath as well as from the sides in the commissure area, and attachment of the sewing ring insert) with the stent frame assembly. As will be explained, the main components of the hybrid valve 340 include a wireform 344 having alternating cusps and commissures that supports the leaflets 342, a lower expandable frame 346 integrated with commissure posts 348, and preferably a sealing ring 350 around the periphery of the cusps of the wireform 344. Several steps in the assembly process will now be described.



FIG. 15A shows the first step in the disclosed method of hybrid valve construction. A piece of PTFE tubular cloth 352 is first partially inverted and placed over the generally tubular stent frame 346 from the bottom, thus covering the inside, outside, and bottom of the frame. Subsequently, the cloth 352 is sewn to the frame 346 through frame holes and around a top circumferential row of struts 354 using an in-and-out stitch with double PTFE thread. FIG. 15B shows the cloth 352 pulled back on the inside and outside after sewing is complete, thereby exposing the top of the stent frame 346. More particularly, the top circumferential row of struts 354 is left partly exposed; at least three peaks intermediate three valleys of the undulating row.



FIG. 16A shows the stent frame 346 covered in the cloth 352 and with a sewing ring insert 356 placed adjacent the top row of struts 354. The cloth layers below the sewing ring 356 have been rough cut, which is acceptable as they are subsequently covered in an outer layer of cloth, thus eliminating the need to “finish” the PTFE cloth in that area. An alternative method would be to fold those layers and finish them on either the top or bottom of the sewing ring.


In FIG. 16B, the sewing ring insert 356 has been stitched to the top of the stent frame 346 in 6 locations to give it a desired scalloped shape. Six locations would be a minimum to define the high (commissures) and low (cusp centers) points of its desired shape. It could be attached at more locations to better define its shape. The PTFE cloth 352 from the inside of the stent frame 346 has been inverted over the sewing ring insert 356 and formed by hand to follow the scalloped shape of the insert. Subsequent to conforming the cloth to the insert as shown, both the inner and outer layers of cloth are sewn together (between the stent frame and the insert).


After the sewing ring formation as shown in FIG. 16B, the next step is to cover three polymer (e.g. PET) commissure tip inserts 360, shown in FIG. 17, with cloth 361, as shown in FIG. 18. Because these inserts 360 are simple 2D parts, they could potentially be sewn on a machine, or “socks” could be knitted to fit over them. Another option could be to use a different cloth, such as PET-based cloth, which could be laser cut and fused to make the covers for the inserts.



FIGS. 19A and 19B shows how the inserts 360 sit with respect to the stent frame 346 and outside of the commissures 362 of a wireform 364. The cloth is not shown in the sketch. The inserts 360 sit directly over the peaks of the upper row of struts 354 of the stent frame 346. The tip inserts 360 and stent frame 346 could be sewn together through holes 366 in the stent frame and a lower hole 368 in the inserts, through their respective layers of cloth. This provides a high degree of vertical stability to the commissures of the assembly. FIGS. 19A and 19B show two different patterns for the holes 368 in the inserts 360, two or three toward the lower end, while FIGS. 17 and 18 show a single hole. Of course, other arrangements are contemplated.


After the cloth-covered commissure inserts 360 are attached to the stent frame/sewing ring assembly, final assembly would be performed. Final assembly would include stitches from below the sewing ring insert 356 (see FIG. 16A) through its hinge point, through the leaflets and wireform cloth, then down through all layers as an in-and-out stitch.


One method of creating commissure inserts uses a polyester (or other material) tip piece 363, similar to that used in the Carpentier-Edwards Model 2700 heart valve, as shown in FIG. 20. The tip piece 363 would have at least one hole 365 in the bottom to facilitate attachment to the expandable stent frame after cloth covering, as well as other holes for securing the cloth, and securing the insert to the wireform cloth.



FIG. 21 shows an example of a PET tubular cloth 366, which could be used to cover the component shown in FIG. 20. The ends of the tube can be knitted closed, as is done on prior art annuloplasty rings, or fused closed with ultrasonic, laser, or heat methods. With one end closed, the piece 364 from FIG. 20 can be inserted from an open end. The cloth 366 can then be folded over to form multiple layers on one side tip piece for subsequent leaflet attachment.



FIGS. 22A and 22B show a commissure insert 368 made in the fashion attached to a cloth-covered expandable stent frame described above. Three such commissure inserts would be attached to the cloth-covered stent frame, which would then be ready for final assembly with the wireform-leaflet assembly. A second method of making commissure inserts uses a non-woven fabric such as Reemay® spunbonded polyester.



FIG. 23 shows solid fabric inserts 370 made in this manner. The inserts 370 can simply be die (or laser, etc.) cut from non-woven fabric sheet of the desired thickness and porosity. These inserts 370 would be immediately ready to attach to the cloth-covered stent frame 372 as shown in FIG. 24. As an alternative to making them from a homogenous sheet, they could be made from a composite that had, for example, a very dense and stiff layer that could face the inside of the valve to add support and minimize leakage, and a less dense layer on the outside that would be easy to stitch to during final valve assembly. For even more stiffness, the composite could contain a layer of polyester sheet, either inserted into a pocket cut into a single, thick section of fabric, or as a layer in a composite structure.



FIGS. 25-31 illustrate alternative integrated anchoring skirt and commissure post subassemblies. As described above with respect to FIGS. 10-13, the subassembly 312 shown in FIG. 10B eliminates the need for annular structural bands, which bands provide stability and rigidity but which impede the ability of the valve to expand post-implant. Each of the alternative subassemblies shown in FIGS. 25-31 also eliminate the need for the structural bands, and further integrate the anchoring skirt and the commissure posts.



FIG. 25A shows a still further assembly 400 of the structural components of a hybrid prosthetic heart valve having an integrated frame member 402 much like those described above but formed of a single piece. A schematic wireform 404 is shown situated on top of the frame member 402 in FIG. 25A, with flexible leaflets and a cloth cover not shown and representing a wireform/leaflet subassembly such as shown at 310 in FIG. 11. The schematic wireform 404 is shown with an outwardly extending sewing flange 406, which may be formed by joined lengths of two fabric tabs that wrap around and cover the wireform. When covered with cloth, the frame member 402 serves as the supportive component for the wireform, leaflets and sealing ring. Further, when covered with cloth, the frame member 402 provides an effective seal against paravalvular leaking (PVL) and circumferential stability to the valve.


The integrated frame member 402, which is also shown in FIGS. 25B-25D, comprises a lower expandable skirt portion 410, an upper annulus band 412, and leaflet support posts 414. The skirt portion 410 comprises a number of chevron patterned or V-shaped struts that can be easily crimped and then expanded. The annulus band 412 provides real estate for the attachment of a sealing ring (not shown), and preferably includes a series of holes around its circumference through which to pass sutures connecting the sealing ring. The integrated frame member 402 includes multiple cuts that enable post-implant expansion and may be laser-cut from a suitable metal such as Elgiloy and electro-polished.


The frame member 402 is desirably formed from a tubular blank of a suitable material, and has a generally circular inflow or lower edge and an undulating outflow or upper edge. More particularly, the upper edge defines three arcuate cusp portions 416 intermediate three upstanding commissure posts 418. The undulating upper edge is shaped to closely fit underneath the wireform 406. After assembling the frame member 402 with the rest of the heart valve components, the skirt portion 410 is typically crimped in a generally conical manner such that its lower edge has a smaller diameter than its upper edge.


Compression/expansion sections 420 along the annulus band 412 are also added to enable a limited collapse of the frame member 402 during delivery. The compression/expansion sections 420 comprise slits formed in the upper edge of the frame member 402 that have spaces enabling a limited compression, and also permit expansion. In a preferred embodiment, solid segments 422 spaced around the annulus band 412 are connected by thin inverted U-shaped bridges 424.


As seen in FIG. 25D, the frame member 402 further includes a number of slits in the region of the commissures 418 to facilitate expansion in general flexibility of the frame member. An elongated central slit 426 extends nearly the entire height of each of the commissures 418. Regions of expandable circumferential struts 428 are positioned within the skirt portion 410 axially aligned with both the compression/expansion sections 420 and the central slits 426. When an outward radial force is applied from within the heart valve having the frame member 402, the annulus band 412 permits expansion because of both the sections 420 and slits 426. Additionally, short arcuate slits 430 are formed at the base of each of the commissure posts 418, generally following a truncated undulating line joining the cusp portions 416. These slits 430 reduce the radial stiffness of the posts 418 such that most of the physiological load absorbed by the flexible leaflets is transferred to the wireform 406, rather than to the posts.


Despite the arcuate slits 430 in the frame member 402 of FIGS. 25A-25D, there are concerns that such an integrated frame design will stiffen the wireform commissure post area, thus altering the load carry mechanism of proven valve platforms. To alleviate such concerns, the three commissure posts may be made of three separate pieces, preferably using polymeric material, such that when connected with the underlining metal frame with sutures, there will not be metal to metal contact.


For instance, FIGS. 26A-26D illustrate an alternative frame member 440 that is configured about the same as the frame member 402, but has separate commissure posts 442. The frame member 440 is shown situated just below a wireform assembly 441 in FIG. 26A. As seen in FIGS. 26C-26D, the annulus band region 444 and the in-flow strut region 446 are exactly same as that of the frame member 402. The only difference is separate commissure posts 442 preferably made of plastic material that will be sewn together with the frame member 440 using sutures 448 before being covered with cloth. A pair of attachment holes 450 is desirably formed in each of the commissure posts 442 for this purpose. As before, the crimpable and expandable frame member 440 without commissure posts is laser-cut and electropolished.


Although the ability to compress and expand the frame members may be an advantage, the present application also contemplates integrated frame members for a hybrid prosthetic heart valves that are not either expandable or compressible. FIGS. 27A-27B show an assembly 460 of the structural components of a hybrid prosthetic heart valve including an integrated frame member 462 with a lower expandable skirt portion 464, an upper annulus band 466, and leaflet support posts 468. The annulus band 466 provides real estate for the attachment of a sealing ring (not shown). As before, the integrated frame member 462 may be laser-cut from a suitable metal tube such as Elgiloy and electro-polished. A wireform 470, such as in the subassembly 310 in FIG. 11, is illustrated just above the undulating upper end of the frame member 462, with flexible leaflets and a cloth cover not shown for clarity.


As seen best in FIG. 27B, the frame member 462 has an outflow or upper edge 472 without capacity for either compression or expansion. That is, a plurality of solid segments 474 spaced around the annulus band 462 are connected by small solid bridges 476. Each of the solid segments 474 preferably has a through hole 478 for use in an attaching a sewing ring around the periphery thereof.



FIG. 28A shows another assembly 480 of the structural components of a prosthetic heart valve including a non-compressible, non-expandable integrated frame member 482 much like the one in FIGS. 27A-27B, but with separated commissure posts 484. Several suture holes 486 in the commissure posts are also added to help secure the commissure posts 484 to an annulus band 488 of the frame member 482, much like is shown in FIG. 26A.



FIG. 25A is a fully integrated frame member 402, with concerns over stiffened commissure posts. The frame member 442 shown in FIG. 26A alleviated that concern with three separate commissure posts 442, but those require sewing together with the expandable frame, which increases the time and steps when assembling the valve. In order to preserve the same load bearing characteristics of the existing commercial valve platforms, while still having a relative easy valve assembly procedure, the embodiments shown in FIGS. 29 and 31 are also contemplated.



FIG. 29 shows an assembly 500 that includes an expandable frame 502 much like the frame 176 described above with respect to FIG. 9A. The frame 502 is secured via sutures to a stent band 504 with upstanding commissures 506 to form an integrated frame member. This stent band 504 is essentially the inner band 95 from FIG. 1A, with suture holes 505 around its circumference to enable secure attachment to the top row of struts of the frame 502. An upper row of struts 508 includes regularly spaced compressible/expandable segments 510 to enable pre-implant compression, and post-implant expansion during a valve-in-valve procedure.


The assembly 500 is again crimpable and expandable. The stent band 504 is formed of a polymer (e.g., polyester) material that is breakable when in expansion force is applied within the valve. This makes the whole valve expandable for valve-in-valve applicable. Because of the polymer commissures 506, the valve load carrying characteristics will be exactly the same as the existing commercial valve platform, thus hydrodynamic performance and durability of the valve shall be the same as the existing commercial valve as well. The relative position of the polyester band and the expandable frame can be assembled as illustrated in FIG. 29, with the stent band 504 positioned immediately above the frame member 502. Conversely, as seen in FIG. 31, the stent band 504 may be located partly radially within the frame 502, in an overlapping manner. This aligns the series of through holes 505 in the stent band 504 with eyeholes 512 provided in the frame 502, which greatly facilitates assembly, thus reducing time and expense.


Some Improvements Over Existing Designs:


1. Integrate the metal stiffener band, the stent frame and/or the polyester band together.


2. The commissure posts, the sewing ring section, as well as the chevron patterned strut section are expandable such that they expand uniformly without distorting the wireform.


3. Reduce the radial stiffness compared with the current heart valve frames so that a transcatheter valve balloon/frame can push the new valve open at least about 2 mm.


4. Integrated commissure posts for holding the leaflet tabs impose reduced or minimal forces on the leaflet, with most of the forces transferred to the wireform


5. No leakage path through the commissure post areas or the sewing ring attachment area.


6. Ease of locating and sewing/clipping/inserting the sewing ring on the frame.


7. During the crimping, expansion, and other manufacturing steps, the frame does not buckle/remains stable, especially at the commissure posts.


8. Crimpability at the annulus region reduces the profile of the valve during valve insertion.


Some Advantages:


1. Expandable hybrid prosthetic heart valves permit valve-in-valve procedures, improving valve performance.


2. Integrated design simplifies assembly, reducing labor and material costs.


3. Crimping the valve reduces its profile, which improves visibility during valve insertion and deployment, enhancing the user's experience.


While the disclosure references particular embodiments, it will understood that various changes and additional variations may be made and equivalents may be substituted for elements thereof without departing from the scope or the inventive concept thereof. In addition, many modifications may be made to adapt a particular situation or device to the teachings herein without departing from the essential scope thereof. Therefore, it is intended that the disclosure not be limited to the particular embodiments disclosed herein, but includes all embodiments falling within the scope of the appended claims.

Claims
  • 1. A hybrid prosthetic heart valve having an inflow end and an outflow end, comprising: a valve member including a fabric-covered undulating wireform with alternating cusps and commissures supporting a plurality of flexible leaflets configured to regulate one-way blood flow therethrough, the valve member having no additional structural bands; anda fabric-covered expandable inflow stent frame having a radially-expandable inflow end and an outflow end that undulates with peaks and valleys corresponding to an inflow end of the wireform, the stent frame being attached to and projecting in an inflow direction from an inflow end of the wireform; anda plurality of separate commissure posts connected to the outflow end of the stent frame and projecting axially therefrom so as to be located radially outward from the wireform commissures, wherein the flexible leaflets pass radially outward through the wireform commissures and attach to the commissure posts, wherein the commissure posts are secured directly on top of and in alignment with the stent frame outflow end, each commissure post having a contoured lower ledge that matches a contour of one of the peaks in the undulating outflow end of the stent frame.
  • 2. The prosthetic heart valve of claim 1, and wherein the stent frame outflow end permits post-implant expansion from a first diameter to an expanded diameter larger than the first diameter upon application of an outward dilatory force from within the outflow end substantially larger than forces associated with normal physiological use.
  • 3. The prosthetic heart valve of claim 2, wherein the stent frame outflow end is configured to be compressed to a constricted diameter smaller than the first diameter.
  • 4. The prosthetic heart valve of claim 1, wherein the stent frame outflow end is non-compressible and non-expandable.
  • 5. The prosthetic heart valve of claim 1, wherein the commissure posts are secured with sutures to the stent frame outflow end.
  • 6. The prosthetic heart valve of claim 1, wherein the commissure posts each includes a portion that extends down below and to the outside of the inflow end of the stent frame and has a through hole which aligns with an eyehole in the stent frame and the commissure post is secured to the stent frame with a suture through the aligned through hole and eyehole.
  • 7. The prosthetic heart valve of claim 1, wherein the commissure posts are formed of a polymer insert covered with fabric.
  • 8. The prosthetic heart valve of claim 1, wherein the commissure posts are formed of a non-woven fabric.
  • 9. The prosthetic heart valve of claim 1, further including a suture-permeable sealing ring enclosed by a portion of the fabric covering the stent frame and extending around a periphery of the outflow end of the stent frame.
  • 10. A hybrid prosthetic heart valve having an inflow end and an outflow end, comprising: a valve member including a fabric-covered undulating wireform with alternating cusps and commissures supporting a plurality of flexible leaflets configured to regulate one-way blood flow therethrough, the valve member having no additional structural bands;a generally tubular fabric-covered expandable inflow stent frame having a radially-expandable inflow end and an outflow end that undulates with peaks and valleys corresponding to an inflow end of the wireform, the outflow end being secured to and projecting from the inflow end of the valve member, wherein the outflow end of the stent frame includes a circumferential structure defining a first diameter that enables physiological functioning of the valve member when implanted, the circumferential structure being radially expandable from the first diameter to a larger expanded diameter upon application of an outward dilatory force from within the stent frame substantially larger than forces associated with normal physiological use, wherein the circumferential structure has limited radially compressibility of between about 7-20% of the first diameter to reduce the size of the outflow end during delivery of the heart valve; anda suture-permeable sealing ring enclosed by a portion of the fabric covering the stent frame and extending around a periphery of the outflow end of the stent frame.
  • 11. The prosthetic heart valve of claim 10, wherein the stent frame includes a plurality of circumferential row struts connected by a series of spaced axial column struts, and the circumferential structure is an outflow row strut that extends continuously around a periphery of the stent frame having peaks and valleys, and the outflow row strut has a series of spaced V-shaped notches that permit limited expansion and contraction.
  • 12. The prosthetic heart valve of claim 10, further including a plurality of separate commissure posts connected to the outflow end of the stent frame and projecting axially therefrom so as to be located radially outward from the wireform commissures, wherein the flexible leaflets pass radially outward through the wireform commissures and attach to the commissure posts.
  • 13. The prosthetic heart valve of claim 12, wherein the commissure posts are secured with sutures to the stent frame outflow end.
  • 14. The prosthetic heart valve of claim 13, wherein the commissure posts are secured directly on top of and in alignment with the stent frame outflow end, each commissure post having a contoured lower ledge that matches a contour of one of the peaks in the undulating outflow end of the stent frame.
  • 15. The prosthetic heart valve of claim 14, wherein the commissure posts each includes a portion that extends down below and to the outside of the inflow end of the stent frame and has a through hole which aligns with an eyehole in the stent frame and the commissure post is secured to the stent frame with a suture through the aligned through hole and eyehole.
  • 16. The prosthetic heart valve of claim 12, wherein the commissure posts are formed of a polymer insert covered with fabric.
  • 17. The prosthetic heart valve of claim 12, wherein the commissure posts are formed of a non-woven fabric.
  • 18. The prosthetic heart valve of claim 10, wherein the sealing ring is formed of silicone inner core.
  • 19. A hybrid prosthetic heart valve having an inflow end and an outflow end, comprising: a valve member including a fabric-covered undulating wireform with alternating cusps and commissures supporting a plurality of flexible leaflets configured to regulate one-way blood flow therethrough, the valve member having no additional structural bands;a generally tubular fabric-covered expandable inflow stent frame having a radially-expandable inflow end and an outflow end that undulates with peaks and valleys corresponding to an inflow end of the wireform, the outflow end being secured to and projecting from the inflow end of the valve member;a suture-permeable sealing ring enclosed by a portion of the fabric covering the stent frame and extending around a periphery of the outflow end of the stent frame; anda plurality of separate commissure posts connected to the outflow end of the stent frame and projecting axially therefrom so as to be located radially outward from the wireform commissures, wherein the flexible leaflets pass radially outward through the wireform commissures and attach to the commissure posts, wherein the commissure posts are secured with sutures to the stent frame outflow end.
  • 20. A hybrid prosthetic heart valve having an inflow end and an outflow end, comprising: a valve member including a fabric-covered undulating wireform with alternating cusps and commissures supporting a plurality of flexible leaflets configured to regulate one-way blood flow therethrough, the valve member having no additional structural bands;a generally tubular fabric-covered expandable inflow stent frame having a radially-expandable inflow end and an outflow end that undulates with peaks and valleys corresponding to an inflow end of the wireform, the outflow end being secured to and projecting from the inflow end of the valve member;a suture-permeable sealing ring enclosed by a portion of the fabric covering the stent frame and extending around a periphery of the outflow end of the stent frame; anda plurality of separate commissure posts connected to the outflow end of the stent frame and projecting axially therefrom so as to be located radially outward from the wireform commissures, wherein the flexible leaflets pass radially outward through the wireform commissures and attach to the commissure posts, wherein the commissure posts are formed of a non-woven fabric.
  • 21. A hybrid prosthetic heart valve having an inflow end and an outflow end, comprising: a valve member including a fabric-covered undulating wireform with alternating cusps and commissures supporting a plurality of flexible leaflets configured to regulate one-way blood flow therethrough, the valve member having no additional structural bands; anda fabric-covered expandable inflow stent frame having a radially-expandable inflow end and an outflow end that undulates with peaks and valleys corresponding to an inflow end of the wireform, the stent frame being attached to and projecting in an inflow direction from an inflow end of the wireform, wherein the stent frame outflow end is non-compressible and non-expandable; anda plurality of separate commissure posts connected to the outflow end of the stent frame and projecting axially therefrom so as to be located radially outward from the wireform commissures, wherein the flexible leaflets pass radially outward through the wireform commissures and attach to the commissure posts.
  • 22. A hybrid prosthetic heart valve having an inflow end and an outflow end, comprising: a valve member including a fabric-covered undulating wireform with alternating cusps and commissures supporting a plurality of flexible leaflets configured to regulate one-way blood flow therethrough, the valve member having no additional structural bands; anda fabric-covered expandable inflow stent frame having a radially-expandable inflow end and an outflow end that undulates with peaks and valleys corresponding to an inflow end of the wireform, the stent frame being attached to and projecting in an inflow direction from an inflow end of the wireform; anda plurality of separate commissure posts connected to the outflow end of the stent frame and projecting axially therefrom so as to be located radially outward from the wireform commissures, wherein the flexible leaflets pass radially outward through the wireform commissures and attach to the commissure posts, wherein the commissure posts are formed of a non-woven fabric.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/199,748, filed Jun. 30, 2016, now issued as U.S. Pat. No. 10,456,246, which claims the benefit of U.S. Application No. 62/188,465, filed Jul. 2, 2015, the entire disclosure of which is incorporated by reference.

US Referenced Citations (478)
Number Name Date Kind
3143742 Cromie Aug 1964 A
3320972 High et al. May 1967 A
3371352 Siposs et al. Mar 1968 A
3409013 Berry Nov 1968 A
3546710 Shumakov et al. Dec 1970 A
3574865 Hamaker Apr 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3656185 Carpentier Apr 1972 A
3657744 Ersek Apr 1972 A
3686740 Shiley Aug 1972 A
3755823 Hancock Sep 1973 A
3839741 Haller Oct 1974 A
4035849 Angell et al. Jul 1977 A
4055861 Carpentier et al. Nov 1977 A
4078468 Civitello Mar 1978 A
4079468 Liotta et al. Mar 1978 A
4084268 Ionescu et al. Apr 1978 A
4106129 Carpentier et al. Aug 1978 A
4164046 Cooley Aug 1979 A
4172295 Batten Oct 1979 A
4217665 Bex et al. Aug 1980 A
4218782 Rygg Aug 1980 A
4259753 Liotta et al. Apr 1981 A
4340091 Skelton et al. Jul 1982 A
4343048 Ross et al. Aug 1982 A
4364126 Rosen et al. Dec 1982 A
4388735 Ionescu et al. Jun 1983 A
4441216 Ionescu et al. Apr 1984 A
4451936 Carpentier et al. Jun 1984 A
4470157 Love Sep 1984 A
4490859 Black et al. Jan 1985 A
4501030 Lane Feb 1985 A
4506394 Bedard Mar 1985 A
4535483 Klawitter et al. Aug 1985 A
4602911 Ahmadi et al. Jul 1986 A
4605407 Black et al. Aug 1986 A
4626255 Reichart et al. Dec 1986 A
4629459 Ionescu et al. Dec 1986 A
4680031 Alonso Jul 1987 A
4687483 Fisher et al. Aug 1987 A
4702250 Ovil et al. Oct 1987 A
4705516 Barone et al. Nov 1987 A
4725274 Lane et al. Feb 1988 A
4731074 Rousseau et al. Mar 1988 A
4778461 Pietsch et al. Oct 1988 A
4790843 Carpentier et al. Dec 1988 A
4851000 Gupta Jul 1989 A
4865600 Carpentier et al. Sep 1989 A
4888009 Lederman et al. Dec 1989 A
4914097 Oda et al. Apr 1990 A
4960424 Grooters Oct 1990 A
4993428 Arms Feb 1991 A
5010892 Colvin et al. Apr 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5041130 Cosgrove et al. Aug 1991 A
5061277 Carpentier et al. Oct 1991 A
5064431 Gilbertson et al. Nov 1991 A
5104407 Lam et al. Apr 1992 A
5147391 Lane Sep 1992 A
5163955 Love et al. Nov 1992 A
5201880 Wright et al. Apr 1993 A
5258021 Duran Nov 1993 A
5258023 Reger Nov 1993 A
5306296 Wright et al. Apr 1994 A
5316016 Adams et al. May 1994 A
5326370 Love et al. Jul 1994 A
5326371 Love et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5376112 Duran Dec 1994 A
5396887 Imran Mar 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411522 Trott May 1995 A
5423887 Love et al. Jun 1995 A
5425741 Lemp et al. Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5449384 Johnson Sep 1995 A
5449385 Religa et al. Sep 1995 A
5450860 O'Connor Sep 1995 A
5469868 Reger Nov 1995 A
5476510 Eberhardt et al. Dec 1995 A
5488789 Religa et al. Feb 1996 A
5489297 Duran Feb 1996 A
5489298 Love et al. Feb 1996 A
5496336 Cosgrove et al. Mar 1996 A
5500016 Fisher Mar 1996 A
5533515 Coller et al. Jul 1996 A
5549665 Vesely et al. Aug 1996 A
5562729 Purdy et al. Oct 1996 A
5571215 Sterman et al. Nov 1996 A
5573007 Bobo, Sr. Nov 1996 A
5578076 Krueger et al. Nov 1996 A
5584803 Stevens et al. Dec 1996 A
5593435 Carpentier et al. Jan 1997 A
5607471 Seguin et al. Mar 1997 A
5626607 Malecki et al. May 1997 A
5628789 Vanney et al. May 1997 A
5674279 Wright et al. Oct 1997 A
5693090 Unsworth et al. Dec 1997 A
5695503 Krueger et al. Dec 1997 A
5713952 Vanney et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5728064 Burns et al. Mar 1998 A
5728151 Garrison et al. Mar 1998 A
5735894 Krueger et al. Apr 1998 A
5752522 Murphy May 1998 A
5755782 Love et al. May 1998 A
5766240 Johnson Jun 1998 A
5776187 Krueger et al. Jul 1998 A
5776188 Shepherd et al. Jul 1998 A
5776189 Khalid Jul 1998 A
5800527 Jansen et al. Sep 1998 A
5814097 Sterman et al. Sep 1998 A
5814098 Hinnenkamp et al. Sep 1998 A
5824064 Taheri Oct 1998 A
5824066 Gross Oct 1998 A
5824068 Bugge Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5848969 Panescu et al. Dec 1998 A
5855563 Kaplan et al. Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5865801 Houser Feb 1999 A
5888240 Carpentier et al. Mar 1999 A
5891160 Williamson, IV et al. Apr 1999 A
5895420 Mirsch, II et al. Apr 1999 A
5902308 Murphy May 1999 A
5908450 Gross et al. Jun 1999 A
5919147 Jain Jul 1999 A
5921934 Teo Jul 1999 A
5921935 Hickey Jul 1999 A
5924984 Rao Jul 1999 A
5928281 Huynh et al. Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5972004 Williamson, IV et al. Oct 1999 A
5972030 Garrison et al. Oct 1999 A
5984959 Robertson et al. Nov 1999 A
5984973 Girard et al. Nov 1999 A
6010531 Donlon et al. Jan 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6059827 Fenton, Jr. May 2000 A
6066160 Colvin et al. May 2000 A
6074418 Buchanan et al. Jun 2000 A
6081737 Shah Jun 2000 A
6083179 Oredsson Jul 2000 A
6099475 Seward et al. Aug 2000 A
6102945 Campbell Aug 2000 A
6106550 Magovern et al. Aug 2000 A
6110200 Hinnenkamp Aug 2000 A
6117091 Young et al. Sep 2000 A
6126007 Kari et al. Oct 2000 A
6143024 Campbell et al. Nov 2000 A
6159240 Sparer et al. Dec 2000 A
6183512 Howanec, Jr. et al. Feb 2001 B1
6187040 Wright Feb 2001 B1
6217610 Carpentier et al. Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6250308 Cox Jun 2001 B1
6258122 Tweden et al. Jul 2001 B1
6264611 Ishikawa et al. Jul 2001 B1
6322526 Rosenman et al. Nov 2001 B1
6332893 Mortier et al. Dec 2001 B1
6348068 Campbell et al. Feb 2002 B1
6350282 Eberhardt Feb 2002 B1
6391054 Carpentier et al. May 2002 B2
6406493 Tu et al. Jun 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6454799 Schreck Sep 2002 B1
6461382 Cao Oct 2002 B1
6491624 Lotfi Dec 2002 B1
6602288 Cosgrove et al. Aug 2003 B1
6602289 Colvin et al. Aug 2003 B1
6619291 Hlavka et al. Sep 2003 B2
6709456 Langberg et al. Mar 2004 B2
6718985 Hlavka et al. Apr 2004 B2
6719786 Ryan et al. Apr 2004 B2
6726717 Alfieri et al. Apr 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6773457 Ivancev et al. Aug 2004 B2
6797002 Spence et al. Sep 2004 B2
6800090 Alferness et al. Oct 2004 B2
6802860 Cosgrove et al. Oct 2004 B2
6805710 Bolling et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6858039 McCarthy Feb 2005 B2
6918917 Nguyen et al. Jul 2005 B1
6921407 Nguyen et al. Jul 2005 B2
6942694 Liddicoat et al. Sep 2005 B2
6955689 Ryan et al. Oct 2005 B2
6966924 Holmberg Nov 2005 B2
6986775 Morales et al. Jan 2006 B2
7018404 Holmberg et al. Mar 2006 B2
7037333 Myers et al. May 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7118595 Ryan et al. Oct 2006 B2
7125421 Tremulis et al. Oct 2006 B2
7166126 Spence et al. Jan 2007 B2
7166127 Spence et al. Jan 2007 B2
7261732 Justino Aug 2007 B2
7276084 Yang et al. Oct 2007 B2
7294148 McCarthy Nov 2007 B2
7381218 Schreck Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7399315 Iobbi Jul 2008 B2
7452376 Lim et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7510575 Spenser et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7534261 Friedman May 2009 B2
7556646 Yang et al. Jul 2009 B2
7585321 Cribier Sep 2009 B2
7625403 Krivoruchko Dec 2009 B2
7780723 Taylor Aug 2010 B2
7806927 Styrc Oct 2010 B2
7871436 Ryan et al. Jan 2011 B2
7998151 St. Goar et al. Aug 2011 B2
8226707 White Jul 2012 B2
8246677 Ryan Aug 2012 B2
8308798 Pintor et al. Nov 2012 B2
8323337 Gurskis et al. Dec 2012 B2
8348998 Pintor et al. Jan 2013 B2
8496700 Edoga et al. Jul 2013 B2
8500802 Lane et al. Aug 2013 B2
8696742 Pintor et al. Apr 2014 B2
9248016 Oba et al. Feb 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9333100 Eberhardt et al. May 2016 B2
9788941 Hacohen Oct 2017 B2
9901448 Pintor et al. Feb 2018 B2
9918836 Hodshon et al. Mar 2018 B2
20010021872 Bailey et al. Sep 2001 A1
20010021874 Carpentier et al. Sep 2001 A1
20010039435 Roue et al. Nov 2001 A1
20010039436 Frazier et al. Nov 2001 A1
20010041914 Frazier et al. Nov 2001 A1
20010041915 Roue et al. Nov 2001 A1
20010049492 Frazier et al. Dec 2001 A1
20020026238 Lane et al. Feb 2002 A1
20020032481 Gabbay Mar 2002 A1
20020058995 Stevens May 2002 A1
20020062150 Campbell et al. May 2002 A1
20020123802 Snyders Sep 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020143386 Davila et al. Oct 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020188348 DiMatteo et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023300 Bailey et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030033009 Gabbay Feb 2003 A1
20030036795 Andersen et al. Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030040793 Marquez Feb 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030109924 Cribier Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030167089 Lane Sep 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20040007895 Egner-Walter Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040044406 Woolfson et al. Mar 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040122514 Fogarty Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040167573 Williamson et al. Aug 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210305 Shu et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040225355 Stevens Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040249452 Adams et al. Dec 2004 A1
20040249453 Cartledge et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050027348 Case et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050043760 Fogarty et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050060029 Le et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050065614 Stinson Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050080454 Drews et al. Apr 2005 A1
20050096738 Cali et al. May 2005 A1
20050096739 Cao May 2005 A1
20050131533 Alfieri et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050159811 Lane Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165479 Drews et al. Jul 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050182486 Gabbay Aug 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216079 MaCoviak Sep 2005 A1
20050222674 Paine Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240259 Sisken et al. Oct 2005 A1
20050251251 Cribier Nov 2005 A1
20050251252 Stobie Nov 2005 A1
20050256567 Lim et al. Nov 2005 A1
20050256568 Lim et al. Nov 2005 A1
20050261765 Liddicoat Nov 2005 A1
20050267572 Schoon et al. Dec 2005 A1
20050278022 Lim Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060015179 Bulman-Fleming et al. Jan 2006 A1
20060020336 Liddicoat Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060025858 Alameddine Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060074484 Huber Apr 2006 A1
20060085060 Campbell Apr 2006 A1
20060095125 Chinn et al. May 2006 A1
20060122634 Ino et al. Jun 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060136054 Berg et al. Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060195184 Lane et al. Aug 2006 A1
20060195185 Lane et al. Aug 2006 A1
20060195186 Drews et al. Aug 2006 A1
20060207031 Cunanan et al. Sep 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060235508 Lane et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060246888 Bender et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060271172 Tehrani Nov 2006 A1
20060271175 Woolfson et al. Nov 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20060293745 Carpentier et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070010876 Salahieh et al. Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016285 Lane et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016287 Cartledge et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070067029 Gabbay Mar 2007 A1
20070078509 Lotfy Apr 2007 A1
20070078510 Ryan Apr 2007 A1
20070100440 Figulla et al. May 2007 A1
20070100441 Kron et al. May 2007 A1
20070129794 Realyvasquez Jun 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070150053 Gurskis et al. Jun 2007 A1
20070156233 Kapadia et al. Jul 2007 A1
20070162103 Case et al. Jul 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070162111 Fukamachi et al. Jul 2007 A1
20070179604 Lane Aug 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070198097 Zegdi Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070203576 Lee et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070225801 Drews et al. Sep 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070239266 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244558 Machiraju Oct 2007 A1
20070255398 Yang et al. Nov 2007 A1
20070260305 Drews et al. Nov 2007 A1
20070265701 Gurskis et al. Nov 2007 A1
20070270944 Bergheim et al. Nov 2007 A1
20070282436 Pinchuk Dec 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080021546 Patz et al. Jan 2008 A1
20080027483 Cartledge et al. Jan 2008 A1
20080033543 Gurskis et al. Feb 2008 A1
20080065198 Quintessenza Mar 2008 A1
20080114452 Gabbay May 2008 A1
20080119875 Ino et al. May 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080188929 Schreck Aug 2008 A1
20080200980 Robin et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080208329 Bishop et al. Aug 2008 A1
20080215144 Ryan et al. Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20080275549 Rowe Nov 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080319543 Lane Dec 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090036903 Ino et al. Feb 2009 A1
20090082857 Lashinski et al. Mar 2009 A1
20090093876 Nitzan et al. Apr 2009 A1
20090192591 Ryan et al. Jul 2009 A1
20090192599 Lane et al. Jul 2009 A1
20090192602 Kuehn Jul 2009 A1
20090192603 Kuehn Jul 2009 A1
20090192604 Gloss Jul 2009 A1
20090192605 Gloss et al. Jul 2009 A1
20090192606 Gloss et al. Jul 2009 A1
20090216322 Le et al. Aug 2009 A1
20090281609 Benichou et al. Nov 2009 A1
20100076548 Konno Mar 2010 A1
20100076549 Keidar et al. Mar 2010 A1
20100161036 Pintor et al. Jun 2010 A1
20100249894 Oba et al. Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100331972 Pintor et al. Dec 2010 A1
20110022165 Oba et al. Jan 2011 A1
20110147251 Hodshon et al. Jun 2011 A1
20110166636 Rowe Jul 2011 A1
20110178597 Navia et al. Jul 2011 A9
20110264207 Bonhoeffer et al. Oct 2011 A1
20110276128 Cao Nov 2011 A1
20120046738 Lau et al. Feb 2012 A1
20120065729 Pintor et al. Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120101570 Tuval et al. Apr 2012 A1
20120150288 Hodshon et al. Jun 2012 A1
20120165928 Nitzan et al. Jun 2012 A1
20130053949 Pintor et al. Feb 2013 A1
20130090725 Pintor et al. Apr 2013 A1
20130116777 Pintor et al. May 2013 A1
20130190862 Pintor et al. Jul 2013 A1
20140188221 Chung et al. Jul 2014 A1
20150366664 Guttenberg et al. Dec 2015 A1
20170000603 Conklin et al. Jan 2017 A1
20170000604 Conklin et al. Jan 2017 A1
20180206986 Noe et al. Jul 2018 A1
Foreign Referenced Citations (16)
Number Date Country
102883684 Jan 2013 CN
0125393 Nov 1984 EP
0143246 Jun 1985 EP
0338994 Oct 1989 EP
1034753 Sep 2000 EP
1755459 Feb 2007 EP
1804726 Jul 2007 EP
1958598 Aug 2008 EP
1116573 Jul 1985 SU
1697790 Dec 1991 SU
9213502 Aug 1992 WO
9742871 Nov 1997 WO
WO-0224118 Mar 2002 WO
2012047644 Apr 2012 WO
2013096854 Jun 2013 WO
2015196152 Dec 2015 WO
Non-Patent Literature Citations (3)
Entry
Krakow, “3F Therapeutics, Inc. Announces the First Clinical Implantation of the 3F Enable Aortic Heart Valve.TM., a Patented, Sutureless Implantation, Replacement Heart Valve Intended to Save Valuable Surgery Time and Reduce Time RelatedComplications . . . ”Healthcare Sales & Marketing Network News Feed, Jan. 18, 2005, pp. 1-2. cited by other.
Sadowski, Jerzy; Kapelak, Boguslaw; Bartus, Krzysztof, “Sutureless Heart Valve lmplantation—A Case Study,” Touch Briefings, 2005, pp. 48-50. cited by other.
International Search Report for International application No. 11201710851S, dated Dec. 27, 2018.
Related Publications (1)
Number Date Country
20200060815 A1 Feb 2020 US
Provisional Applications (1)
Number Date Country
62188465 Jul 2015 US
Continuations (1)
Number Date Country
Parent 15199748 Jun 2016 US
Child 16666331 US